drugset
drugset / Trial / NCT03641794

Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers

NCT03641794 ↗

Phase 1 Unknown 56 enrolled Jiangxi Qingfeng Pharmaceutical Co. Ltd. Shanghai De Novo Pharmatech Co., Ltd. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a double blind Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of DN1406131, an investigational agent intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme and tryptophan 2,3-Dioxygenase 2 (TDO-2) and help the human immune system attack solid tumor cells more effectively.

Timeline

Start
2018-09-07
Primary completion
2019-05-13
Completion
2019-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject DN1406131 Unknown 25 mg Oral
Subject DN1406131 Unknown 50 mg Oral
Subject DN1406131 Unknown 100 mg Oral
Subject DN1406131 Unknown 200 mg Oral
Subject DN1406131 Unknown 400 mg Oral
Subject DN1406131 Unknown 600 mg Oral
Subject DN1406131 Unknown 800 mg Oral

Indications

cancer